This article was originally published in The Gray Sheet
Proteomics collaboration with Hitachi and Oracle to identify drug targets is prepping to go public, according to the firm. Collaborators on the project, which is currently dubbed Myriad Proteomics, are waiting for amenable market conditions to launch an initial public offering. The operation, including a fully functioning data-generating facility in Salt Lake City with a 65-member staff, was launched in 2001 to compete with Celera Genomics (1"The Gray Sheet" April 23, 2001, In Brief). Myriad contributed $82 mil. in technology to the alliance, retaining a 50% stake in the $185 mil. venture...
You may also be interested in...
Proteomics collaboration with Hitachi and Oracle may include development of diagnostics and therapeutics as well as primary goal of creating a proprietary database to be marketed to other pharmaceutical and biotechnology companies, the firm says. Valued at $185 mil., the alliance to map the human proteome in less than three years will compete with proteomics firm Celera Genomics. Myriad will contribute $82 mil. in technology to the alliance and retain a 50% stake. Electronics firm Hitachi, software company Oracle and investment banking firm Friedli Corporate Finance will contribute $85 mil. in cash, plus $18 mil. in technology
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’